

HOTLINE: Effective August 16, 2021

New Test **3001839** **Emery-Dreifuss Muscular Dystrophy Panel, Sequencing** **EDMD NGS**



Additional Technical Information



Patient History for Emery-Dreifuss Muscular Dystrophy (EDMD) Testing

Methodology: Massively Parallel Sequencing
Performed: Varies
Reported: 3-6 weeks

Specimen Required: Collect: Lavender (EDTA) or Yellow (ACD Solution A or B).
Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens
Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval: By report

Interpretive Data:
Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Genes Tested: *EMD, FHL1, LMNA*

CPT Code(s): 81479; 81404; 81406

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.